Previous Close | 32.43 |
Open | 33.80 |
Bid | 32.77 x 400 |
Ask | 32.88 x 100 |
Day's Range | 32.65 - 33.97 |
52 Week Range | 13.57 - 53.08 |
Volume | |
Avg. Volume | 763,969 |
Market Cap | 2.242B |
Beta (5Y Monthly) | 1.89 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.62 |
Earnings Date | May 06, 2024 - May 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 69.89 |
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas. Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside ch
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).